Cargando…
Human Vaccines & Immunotherapeutics: News
Oncolytic immunotherapy reduces the size of melanoma tumors in phase 3 trial EV71 vaccine protects children against HFMD Influenza vaccination important for risk groups Bharat‘s rotavirus vaccine is safe and modestly efficacious Successfully avoiding the cold-chain for vaccines FDA approval for Stal...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896609/ https://www.ncbi.nlm.nih.gov/pubmed/25290656 http://dx.doi.org/10.4161/hv.29344 |
| _version_ | 1782436032211320832 |
|---|---|
| author | Riedmann, Eva M. |
| author_facet | Riedmann, Eva M. |
| author_sort | Riedmann, Eva M. |
| collection | PubMed |
| description | Oncolytic immunotherapy reduces the size of melanoma tumors in phase 3 trial EV71 vaccine protects children against HFMD Influenza vaccination important for risk groups Bharat‘s rotavirus vaccine is safe and modestly efficacious Successfully avoiding the cold-chain for vaccines FDA approval for Stallergenes’ sublingual grass pollen allergy immunotherapy HPV vaccination campaign could change from three to two doses in the UK Valneva continues phase 2/3 trial of Pseudomonas aeruginosa vaccine |
| format | Online Article Text |
| id | pubmed-4896609 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-48966092016-06-17 Human Vaccines & Immunotherapeutics: News Riedmann, Eva M. Hum Vaccin Immunother News, Policy & Profiles Oncolytic immunotherapy reduces the size of melanoma tumors in phase 3 trial EV71 vaccine protects children against HFMD Influenza vaccination important for risk groups Bharat‘s rotavirus vaccine is safe and modestly efficacious Successfully avoiding the cold-chain for vaccines FDA approval for Stallergenes’ sublingual grass pollen allergy immunotherapy HPV vaccination campaign could change from three to two doses in the UK Valneva continues phase 2/3 trial of Pseudomonas aeruginosa vaccine Taylor & Francis 2014-05-01 /pmc/articles/PMC4896609/ /pubmed/25290656 http://dx.doi.org/10.4161/hv.29344 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | News, Policy & Profiles Riedmann, Eva M. Human Vaccines & Immunotherapeutics: News |
| title | Human Vaccines & Immunotherapeutics: News
|
| title_full | Human Vaccines & Immunotherapeutics: News
|
| title_fullStr | Human Vaccines & Immunotherapeutics: News
|
| title_full_unstemmed | Human Vaccines & Immunotherapeutics: News
|
| title_short | Human Vaccines & Immunotherapeutics: News
|
| title_sort | human vaccines & immunotherapeutics: news |
| topic | News, Policy & Profiles |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896609/ https://www.ncbi.nlm.nih.gov/pubmed/25290656 http://dx.doi.org/10.4161/hv.29344 |
| work_keys_str_mv | AT riedmannevam humanvaccinesimmunotherapeuticsnews |